Lixte Biotechnology Holdings LIXT 深 沪
已收盘 10-10 16:00:00 美东时间
4.77
-0.030
-0.62%
华盛通- 最 高4.90
- 今 开4.78
- 成交量 14.08万股
- 最 低 4.495
- 昨 收 4.80
- 总市值 2175.79万
- 52周最高 6.26
- 市盈率 静 --
- 换手率 3.09%
- 52周最低 0.64
- 委 比 -97.82%
- 总股本 456.14万
- 历史最高 71.90
- 量 比 1.46
- 振 幅 8.44%
- 历史最低 0.64
- 每 手 1
- 风险率 1.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lixte Biotechnology Invests $2.6M in Cryptocurrencies
The latest announcement is out from Lixte Biotechnology Holdings ( ($LIXT) ). O...
09-12 01:47
LIXTE Biotechnology makes $2.6M initial purchase of digital currency
LIXTE Biotechnology (NASDAQ:LIXT) said on Wednesday that it has made an initial purchase of cryptocurrencies to further diversify its treasury holdings and for potential acquisitions. The company purc...
09-11 04:17
LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions
LIXTE Biotechnology Holdings, Inc. ("LIXTE") announced the purchase of 10.5 Bitcoin (BTC) and 300 Ethereum (ETH) totaling approximately $2.6 million to diversify its treasury and facilitate potential acquisitions. Cryptocurrency now constitutes about 43.6% of LIXTE's treasury holdings, with the Board approving up to 50% allocation to digital assets. CEO Geordan Pursglove emphasized the strategic importance of integrating cryptocurrencies to enhan...
09-10 20:05
Lixte Biotechnology appoints new CFO and board members
Lixte Biotechnology (NASDAQ:LIXT) appointed Peter Stazzone as chief financial officer. Lourdes Felix and Guy Primus joined LIXTE’s board of directors. Former CFO Robert Weingarten and board members Ba...
09-03 20:18
LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer
LIXTE Biotechnology Holdings announced the addition of Peter Stazzone as Chief Financial Officer and Lourdes Felix and Guy Primus to its Board of Directors, succeeding Bas van der Baan and René Bernards. The company has relocated its headquarters to Boca Raton, Florida, aiming to enhance operational efficiency and reduce costs. Stazzone brings over 20 years of financial management experience, while Felix and Primus add expertise in corporate fina...
09-03 12:00
24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets
LIXTE Biotechnology Holdings, Inc. is advancing its lead compound, LB-100, in clinical trials targeting MSS colorectal cancer, ovarian clear-cell carcinoma, and soft-tissue sarcoma. LB-100 aims to enhance chemotherapy and immunotherapy effectiveness. Trials in MSS colorectal cancer, ovarian clear-cell carcinoma, and soft-tissue sarcoma are ongoing, with interim data expected soon. The company focuses on high-need cancer indications via combinatio...
08-25 12:05
24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100
LIXTE Biotechnology’s lead compound LB-100, a first-in-class PP2A inhibitor, is highlighted in a Nature Reviews Cancer editorial for its innovative approach to cancer therapy. Unlike traditional methods, LB-100 hyperactivates oncogenic pathways, pushing cancer cells into a stress-induced collapse, and has shown promise in preclinical and clinical studies, including tumor regression in colorectal and pancreatic models. The compound’s mechanism, wh...
08-19 15:18
LIXTE Biotechnology Holdings Provides Corporate Update
LIXTE Biotechnology Holdings, Inc. has completed two financings, raising $6.5 million, and regained compliance for continued listing on Nasdaq. The company appointed Geordan Pursglove as Chairman and CEO, and Bas van der Baan as President and Chief Scientific Officer. Two new board members, Jason Sawyer and Michael Holloway, MD, were added. LIXTE’s compound LB-100 received validation through a study published in *Nature*, showing improved surviva...
08-18 12:00
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025
LIXTE Biotechnology Holdings announced advancements in its lead compound LB-100, a first-in-class PP2A inhibitor targeting ovarian clear cell carcinoma, advanced soft tissue sarcoma, and MSS metastatic colon cancer. Upcoming 2025 catalysts include interim efficacy data for OCCC (Q4), PFS/ORR updates for STS (Q3), and biomarker data for MSS colon cancer (Q4). LB-100's potential to enhance DNA damage response and overcome treatment resistance posit...
08-14 12:05
每日数字货币动态汇总（2025-08-14）
1. 特朗普家族支持的矿企ABTC加速增持比特币，目前储备量达2130枚BTC 特朗普家族支持的美国比特币公司（ABTC）近期加速了比特币的收购，于7月1日至...
08-14 09:04
